# A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer

Source: https://onco.cc/trials/nct07591090/  
OnCo record `nct07591090` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of AK146D1 in advanced solid tumours, run by Akeso, now recruiting.

## Summary

A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer is a phase 2 interventional study registered as NCT07591090 by Akeso, with 200 participants planned, started 2026-07-17 and due to reach its primary completion in 2027-09-01. Interventions recorded: AK146D1 for injection and AK112 Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07591090
- Phase: 2
- Setting: A Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of AK146D1 Combined With AK112 in Patients With Advanced Breast Cancer
- Sponsor: Akeso
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT07591090: https://clinicaltrials.gov/study/NCT07591090

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [AK146D1](https://onco.cc/drugs/ak146d1/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct07591090.json